Background:Muscle strain injuries are extremely common in sports medicine. Muscle healing often is hindered by scar tissue formation after injury.
Hypothesis:Suramin can prevent scar tissue formation and improve muscle healing after injury because of its ability to antagonize transforming growth factor– •1, a fibrotic cytokine.
Study Design:Controlled laboratory study.
Materials and Methods:In vitro, muscle-derived fibroblasts (a potential cell source of muscle fibrosis) were incubated with suramin and/or transforming growth factor– •1; a cell growth curve was obtained. In vivo, mouse gastrocnemius muscles were strain injured. Suramin or sham/control intramuscular injections were performed after injury at various time points. Mice were sacrificed at various time points after injury, and skeletal muscle tissue was evaluated by using histological and physiological tests. Statistical analysis was performed by using analysis of variance and Fisher tests.
Results:Suramin decreased the stimulating effect of transforming growth factor– •1 on the growth of muscle-derived fibroblasts in vitro. Significantly less fibrous scar formation was observed in suramin-treated muscles than in sham-injected muscles. The fast-twitch and tetanus strength of suramin-treated muscles was also significantly greater relative to that of control muscles.
Conclusions:Suramin blocked the stimulatory effect of transforming growth factor– •1 on muscle-derived fibroblasts in vitro. Suramin also reduced fibrous scar formation in muscle and enhanced muscle strength in strain-injured skeletal muscle.
Clinical Relevance:These results may facilitate the development of strategies to enhance muscle healing after injury.
Aronen JG, Chronister RO. Quadriceps contusion: hastening the return to play. Physician Sportsmed. 1992;20:130-136.
2.
Aronen JG, Chronister RO, Ove PN, et al. Thigh contusions: minimizing the length of time before return to full athletic activities with early immobilization in 120 ° of knee flexion. Am J Sports Med. 1990;18:547-551.
3.
Bernasconi P, Di Blasi C, Mora M, et al. Transforming growth factor-•1 and fibrosis in congenital muscular dystrophy. Neuromuscul Disord. 1999;9:28-33.
4.
Bernasconi P, Torchiana E, Confalonieri P, et al. Expression of transforming growth factor-• in dystrophic patient muscles correlates with fibrosis: pathogenetic role of a fibrogenic cytokine. J Clin Invest. 1995;96:1137-1144.
5.
Bischoff R. The satellite cell and muscle regeneration. In: Engel AG, Franzini-Armstrong C, eds. Myology. 2nd ed.New York, NY: McGraw-Hill; 1994:97-118.
6.
Border WA, Noble NA. Transforming growth factor-• in tissue fibrosis. N Engl J Med. 1994;10:1286-1292.
7.
Caplan A, Carlson B, Faulkner J, et al. Skeletal muscle. In: Woo SLY, Buckwalter JA, eds. Injury and Repair of the Musculoskeletal Soft Tissue. Park Ridge, Ill: American Academy of Orthopaedic Surgeons; 1988:213-291.
8.
Carlson BM, Faulkner JA. The regeneration of skeletal muscle fibers following injury: a review. Med Sci Sports Exerc. 1983;15:187-196.
9.
Chamberlain J, Shah M, Ferguson MW. The effect of suramin on healing adult rodent dermal wounds. J Anat. 1995;186:87-96.
10.
Confalonieri P, Bernasconi P, Cornelio F, et al. Transforming growth factor-•1 in polymyositis and dermatomyositis correlates with fibrosis but not with mononuclear cell infiltrate. J Neuropathol Exp Neurol. 1997;56:479-484.
11.
Crisco JJ, Jokl P, Heinen GT, et al. A muscle contusion injury model: biomechanics, physiology, and histology. Am J Sports Med. 1994;22:702-710.
12.
Feuillan P, Raffeld M, Stein CA, et al. Effects of suramin on the function and structure of the adrenal cortex in the cynomolgus monkey. J Clin Endocrinol Metab. 1987;65:153-158.
13.
Florini JR, Ewton DZ, Coolican SA. Growth hormone and the insulinlike growth factor system in myogenesis. Endocr Rev. 1996;17:481-517.
14.
Florini JR, Magri KA. Effect of growth factors on myogenic differentiation. Am J Physiol. 1989;256:C701-C711.
15.
Foster W, Li Y, Usas A, et al. Gamma interferon as an antifibrosis agent in skeletal muscle. J Orthop Res. 2003;21:798-804.
16.
Fukushima K, Badlani N, Usas A, et al. The use of an antifibrosis agent to improve muscle recovery after laceration. Am J Sports Med. 2001;29:394-402.
17.
Garrett WE. Muscle strain injuries. Am J Sports Med. 1996;24:S2-S8.
18.
Garrett WE Jr. Muscle strain injuries: clinical and basic aspects. Med Sci Sports Exerc. 1990;22:436-443.
19.
Hannafin JA, Pedowitz RA, Hidaka C, et al. Pathophysiology and healing of musculoskeletal tissues. In: Griffin LY, ed. Orthopaedic Knowledge Update: Sports Medicine. Rosemont, Ill: American Academy of Orthopaedic Surgeons; 1994:17-33.
20.
Hawking F. Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother. 1987;106:216-221.
21.
Holbrook TL, Grazier K, Kelsey JL, et al. The Frequency of Occurrence, Impact and Cost of Selected Musculoskeletal Conditions in the United States. Chicago, Ill: American Academy of Orthopaedic Surgeons; 1984.
22.
Huard J, Li Y, Fu F.Muscle injury and repair: current trends in research. J Bone Joint Surg Am. 2002;84:822-832.
23.
Hurme T, Kalimo H. Activation of myogenic precursor cells after muscle injury. Med Sci Sports Exerc. 1992;24:197-205.
24.
Isaka Y, Brees DK, Ikegaya K, et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med. 1996;2:418-423.
25.
Jarvinen M, Lehto MUK. The effect of early mobilization and immobilization on the healing process following muscle injuries. Sports Med. 1993;15:78-89.
26.
Jarvinen TA, Kaariainen M, Jarvinen M, et al. Muscle strain injuries. Curr Opin Rheumatol. 2000;12:155-161.
27.
Johnson SE, Allen RE. Activation of skeletal muscle satellite cells and the role of fibroblast growth factor receptors. Exp Cell Res. 1995;219:449-453.
28.
Kalimo H, Rantanen J, Jarvinen M. Soft tissue injuries in sport. Baillieres Clin Orthop. 1997;2:1-24.
29.
Kasemkijwattana C, Menetrey J, Bosch P, et al. Use of growth factors to improve muscle healing after strain injury. Clin Orthop. 1999;370:272-285.
30.
Kasemkijwattana C, Menetrey J, Day CS, et al. Biologic intervention in muscle healing and regeneration. Sports Med Arthrosc Rev. 1998;6:95-102.
31.
Kasemkijwattana C, Menetrey J, Somogyl G, et al. Development of approaches to improve the healing following muscle contusion. Cell Transplant. 1998;7:585-598.
32.
La Rocca RV, Meer J, Gilliatt RW. Suramin-induced polyneuropathy. Neurology. 1990;40:954-960.
33.
Lehto M, Jarvinen M, Nelimarkka O. Scar formation after skeletal muscle injury: a histological and autoradiographical study in rats. Arch Orthop Trauma Surg. 1986;104:366-370.
34.
Levine A, Gill P, Cohen J, et al. Suramin antiviral therapy in the acquired immunodeficiency syndrome. Ann Intern Med. 1986;105:32-37.
35.
Li Y, Cummins J, Huard J. Muscle injury and repair. Curr Opin Orthop. 2001;12:409-415.
36.
Li Y, Foster W, Deasy B, et al. TGF-•1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle, a key event in muscle fibrogenesis. Am J Pathol. 2004;164:1007-1019.
37.
Li Y, Huard J. Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle. Am J Pathol. 2002;161:895-907.
38.
Mak JW, Lam PL, Choong MF, et al. Antifilarial activity of intravenous suramin and oral diethylcarbamazine citrate on subperiodic Brugia malayi in the leaf-monkey, Presbytis cristata. J Helminthol. 1990;64:96-99.
39.
Menetrey J, Kasemkijwattana C, Day CS, et al. Growth factors improve muscle healing in vivo. J Bone Joint Surg Br. 2000;82:131-137.
40.
Menetrey J, Kasemkijwattana C, Fu FH, et al. Suturing versus immobilization of a muscle laceration: a morphological and functional study in a mouse model. Am J Sports Med. 1999;27:222-229.
41.
Mietz H, Chevez-Barrios P, Feldman RM, et al. Suramin inhibits wound healing following filtering procedures for glaucoma. J Ophthalmol. 1998;82:816-820.
Nikolaou PK, Macdonald BL, Glisson RR, et al. Biomechanical and histological evaluation of muscle after controlled strain injury. Am J Sports Med. 1987;15:9-14.
44.
Qu Z, Balkir L, Van Deutekom JCT, et al. Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol. 1998;142:1257-1267.
45.
Quinn LS, Haugk KL. Overexpression of the type-1 insulin-like growth factor receptor increases ligand-dependent proliferation and differentiation in bovine skeletal myogenic culture. J Cell Physiol. 1996;168:34-41.
46.
Rando TA, Blau HM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol. 1994;125:1275-1287.
47.
Sato K, Li Y, Foster W, et al. Improvement of muscle healing through enhancement of muscle regeneration and prevention of fibrosis. Muscle Nerve. 2003;28:365-372.
48.
Schrell UMH, Gauer S, Kiesewetter F, et al. Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phase, extracellular growth factors, and PDGF-BB autocrine growth loop. J Neurosurg. 1995;82:600-607.
49.
Stein CA. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res. 1993;53:2239-2248.
50.
Taylor DC, Dalton JD Jr, Seaber AV, et al. Experimental muscle strain injury: early functional and structural deficits, and the increased risk for re-injury. Am J Sports Med. 1993;21:190-194.
51.
Tiggelman AMBC, Linthorst C, Boers W, et al. Transforming growth factor-• –induced collagen synthesis by human liver myofibroblasts inhibited by •2-macroglobulin. J Hepatol. 1997;26:1220-1228.
52.
Zhang H-Y, Phan SH. Inhibition of myofibroblast apoptosis by transforming growth factor •1. Am J Respir Cell Mol Biol. 1999;21:658-665.
53.
Zhao J, Sime PJ, Bringas P Jr, et al. Adenovirus-mediated decorin gene transfer prevents TGF-beta–induced inhibition of lung morphogenesis. Am J Physiol. 1999;277:L412-L422.
54.
Zumkeller W, Schofield PN. Growth factors, cytokines and soluble forms of receptor molecules in cancer patients. Anticancer Res. 1995;15:344-348.
